Serum interleukin-6 levels at the start of the second course of atezolizumab plus bevacizumab therapy predict therapeutic efficacy in patients with advanced hepatocellular carcinoma: a multicenter analysis.
Takanori SuzukiKentaro MatsuuraYuta SuzukiFumihiro OkumuraYoshihito NaguraSatoshi SobueSho MatoyaTomokatsu MiyakiYoshihide KimuraAtsunori KusakabeSatoshi NaraharaTakayuki TokunagaKatsuya NagaokaShuko MurakamiTakako InoueKeita KuroyanagiHayato KawamuraKei FujiwaraShunsuke NojiriHiromi KataokaYasuhito TanakaPublished in: Journal of gastroenterology and hepatology (2024)
Serum levels of IL-6 at the initiation of the second course of treatment may predict Atez + Bev efficacy and prognosis in HCC.